LILRB2 Antibodies and Uses Thereof - Cancer and Autoimmune Treatment
Summary
The USPTO granted patent US12596122B2 to The Board of Regents of the University of Texas System covering LILRB2 antibodies and their uses for detecting and treating cancer and autoimmune diseases. The patent names 11 inventors and includes 26 claims. The filing date was January 28, 2021, under application number 17759800.
What changed
The USPTO issued patent US12596122B2 to The Board of Regents of the University of Texas System, granting exclusive intellectual property rights to LILRB2 antibodies for cancer and autoimmune disease applications. The patent includes claims covering the antibody compositions and methods of using them for detection and treatment purposes.
For pharmaceutical and biotechnology companies developing immunotherapies or antibody-based therapeutics, this patent may affect freedom-to-operate considerations. Entities conducting research in the LILRB2/ILT4 space should evaluate potential licensing needs or design-around strategies to avoid infringement on the granted claims.
What to do next
- Monitor patent portfolio for freedom-to-operate implications
- Review licensing opportunities for LILRB2 antibody technology
- Assess competitive landscape for similar antibody therapies
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
LILRB2 antibodies and uses thereof
Grant US12596122B2 Kind: B2 Apr 07, 2026
Assignee
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Inventors
Zhiqiang An, Ningyan Zhang, Zhiqiang Ku, Chengcheng Zhang, Xiaoye Liu, Heyu Chen, JingJing Xie, Maria Jose Costa, An Song, X. Charlene Liao
Abstract
Provided herein are antibodies binding to LILRB2 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.
CPC Classifications
A61K 47/6849 A61P 35/00
Filing Date
2021-01-28
Application No.
17759800
Claims
26
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.